AIFA
Vertex to acquire Crinetics in deal worth around $10bn
The deal includes an approved treatment for acromegaly and other pipeline candidates
Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE
The rare inherited disease affects approximately 11,000 people in the UK
Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval
The rare inherited disease affects more than 109,000 people worldwide
Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA
Over 11,000 people in the UK are affected by the rare genetic disease
FDA grants rare paediatric disease designation to Enterprise’s cystic fibrosis candidate
The genetic disease is estimated to affect more than 100,000 people globally
Vertex shares positive late-stage results for triple combination cystic fibrosis treatment
The company compared the treatment to its current triple cystic fibrosis therapy
MHRA extends licence of Vertex’s cystic fibrosis drugs for young children
Kaftrio and Kalydeco are now approved for use in certain patients aged two to five years
Pioneering research collaboration seeks cure for cystic fibrosis
Backed by the non-profit Cystic Fibrosis Foundation and venture capital group Flagship, Pioneering Medicines will identify and develop genetic therapies for CF
Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production
Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn
A new deal will see Vertex harness Arbor Biotechnologies gene-editing technology to enhance its discovery efforts
Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
Amended agreement sees Vertex take control of gene therapy programme
Vertex gains FDA fast track designation for diabetes stem cell therapy
Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients